SCALPEL Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination
- Coordinator
- Oslo Universitetssykehus Hf, Norway
- Runs
- 1 March 2025 to 31 August 2029
- Status
- Running
- EU funding
- €4.6m
- Total cost
- €4.6m
- Partners
- 6 organisations in 5 countries
- Type
- European Innovation Council
- Grant agreement
- 101185509
What the project is doing
In the project's own words, from its summary on CORDIS.
Cancer ranks as a major cause of death, with 3.4 million new incidences in 2020 in Europe. The current cancer standards of care include surgery, chemotherapy, radiotherapy and, as of late, immunotherapy, none of which have met their expected therapeutic outcome yet. Photomedical treatments like photodynamic therapy of cancer (PDT) and Photochemical Internalisation (PCI) show great promise as effective anticancer treatments.
Both are, however, limited by the cancer cells left behind, causing cancer recurrence and metastasis, after recovering from their sublethal membrane injuries. But what, if we could label these injured cancer cells with antibodies, thus activating the immune system to eradicate them? SCALPEL will utilize PDT or PCI to destroy the bulk of tumour cells while marking the remaining sub-lethally damaged cancer cells for destruction, by attaching antibodies to their membranes.
Bespoke, modified SCALPEL components will be administered to all cells, normal and cancerous. Following local irradiation, only the photo-modified components will conjugate with our specially engineered antibodies, selectively flagging the cancer cells, for destruction. Moreover, the immune system will be trained through this process, against the specific cancers offering systemic immunity. The high risk/high gain nature of SCALPEL is counterbalanced by an avant-garde, multidisciplinary research team, covering photomedicine/photobiology, immunology, synthetic chemistry, porphyrin chemistry and protein engineering.
SCALPEL is expected to revolutionize oncology by offering a pioneering photoimmunotherapy with curative potential. In this project, we strive to provide a proof-of-principle of the proposed technology in cell cultures, but also in laboratory animals, with the long term-vision of establishing SCALPEL as a clinical cancer modality.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Oslo Universitetssykehus Hf | Oslo | Norway | Coordinator |
| Eurice European Research and Project Office GmbH | St Ingbert | Germany | Participant |
| Ethniko Kai Kapodistriako Panepistimio Athinon | Athina | Greece | Participant |
| Institut Gustave Roussy | Villejuif | France | Participant |
| PorphyChem | Longvic | France | Participant |
| Kemijski Institut | Ljubljana | Slovenia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI